Search alternatives:
μ decrease » a decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ms decrease » a decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
ng decrease » nn decrease (Expand Search), a decrease (Expand Search), we decrease (Expand Search)
_ decrease » _ decreased (Expand Search)
100 ng » 100 mg (Expand Search), 100 nm (Expand Search), 100 ns (Expand Search)
μ decrease » a decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ms decrease » a decrease (Expand Search), nn decrease (Expand Search), mean decrease (Expand Search)
ng decrease » nn decrease (Expand Search), a decrease (Expand Search), we decrease (Expand Search)
_ decrease » _ decreased (Expand Search)
100 ng » 100 mg (Expand Search), 100 nm (Expand Search), 100 ns (Expand Search)
-
1
-
2
-
3
SLE decreases risk for hormonal cancers.
Published 2021“…(b) Prostate cancer incidence in male SLE cohort is significantly decreased by SLE status (OR 0.23, 95% CI 0.089, 0.50, p = 0.0053).…”
-
4
-
5
-
6
-
7
-
8
-
9
DART-ID decreases missing datapoints across runs.
Published 2019“…Only peptides seen in >50% of experiments are included. (<b>b</b>) Decrease in missing data across all runs after applying DART-ID, for SCoPE-MS and the two bulk sets from <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1007082#pcbi.1007082.g004" target="_blank">Fig 4</a> at 1% FDR. …”
-
10
mGluR5 receptor decreased glycinergic currents.
Published 2019“…(<b>E</b>) The inhibitory effect of CHPG on GlyR-IPSCs was not blocked by intracellularly loaded GDP-β-S (62.3 ± 6.4% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.782, <i>p</i> = 0.032), chelerythrine (60.9 ± 11.3% of baseline at 15–20 min post-CHPG, <i>t</i>[6] = 2.705, <i>p</i> = 0.035), or Ro-32-0432 (69.9 ± 3.2% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 8.495, <i>p</i> < 0.001). (<b>F</b>) Postsynaptic loading of U-0126 or PD98059 prevented CHPG from decreasing glycinergic responses (U-0126, 107.6 ± 10.4% of baseline at 15–20 min post-CHPG, <i>t</i>[8] = 0.997, <i>p</i> = 0.348; PD98059, 93.1 ± 5.0% of baseline at 15–20 min post-CHPG, <i>t</i>[5] = 0.883, <i>p</i> = 0.418). …”
-
11
-
12
-
13
-
14
-
15
-
16
ABT199 inhibits ALK <sup>mutant</sup> kinase activity and decreases it phosphorylation.
Published 2025Subjects: -
17
-
18
-
19
-
20